Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ESSA Pharma ( (EPIX) ) just unveiled an update.
ESSA Pharma has reported a net loss of $8.5 million for the first fiscal quarter of 2025, following the termination of its masofaniten clinical trials. The company is exploring several strategic options, such as mergers or asset sales, to maximize shareholder value, which may involve cost reductions.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was focused on developing novel therapies for the treatment of prostate cancer before discontinuing its clinical trials and development programs.
YTD Price Performance: -9.29%
Average Trading Volume: 323,889
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $75.02M
Find detailed analytics on EPIX stock on TipRanks’ Stock Analysis page.